Cargando…

Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer

BACKGROUND: Significant progress in treatment of metastatic castration resistant prostate cancer (mCRPC) has been made. Biomarkers to tailor therapy are scarce. To facilitate decision-making we evaluated dynamic changes of alkaline phosphatase (ALP), lactate dehydrogenase (LDH) and prostate specific...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mikah, Phillip, Krabbe, Laura-Maria, Eminaga, Okyaz, Herrmann, Edwin, Papavassilis, Philipp, Hinkelammert, Reemt, Semjonow, Axel, Schrader, Andres-Jan, Boegemann, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4790058/ https://www.ncbi.nlm.nih.gov/pubmed/26975660 http://dx.doi.org/10.1186/s12885-016-2260-y

Ejemplares similares

Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer
por: Schlack, Katrin, et al.
Publicado: (2016)

The prognostic potential of alkaline phosphatase and lactic acid dehydrogenase in bmCRPC patients without significant PSA response under enzalutamide
por: Poteska, Renata, et al.
Publicado: (2022)

A prognostic score for overall survival in patients treated with abiraterone in the pre- and post-chemotherapy setting
por: Boegemann, Martin, et al.
Publicado: (2019)

CMDX©-based single source information system for simplified quality management and clinical research in prostate cancer
por: Eminaga, Okyaz, et al.
Publicado: (2012)

Influence of Statins on Survival Outcome in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Abiraterone Acetate
por: Boegemann, Martin, et al.
Publicado: (2016)

Clinical map document based on XML (cMDX): document architecture with mapping feature for reporting and analysing prostate cancer in radical prostatectomy specimens
por: Eminaga, Okyaz, et al.
Publicado: (2010)

The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone
por: Boegemann, Martin, et al.
Publicado: (2017)

Androgen dynamics and serum PSA in patients treated with abiraterone acetate
por: Ryan, C J, et al.
Publicado: (2014)

Association of early PSA decline and time to PSA progression in abiraterone acetate-treated metastatic castration-resistant prostate cancer; a post-hoc analysis of Japanese phase 2 trials
por: Nakayama, Masahiko, et al.
Publicado: (2016)

PSA Kinetics as Prognostic Markers of Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate
por: España, Sofia, et al.
Publicado: (2020)

ALP bouncing and LDH normalization in bone metastatic castration-resistant prostate cancer patients under therapy with Enzalutamide: an exploratory analysis
por: Schlack, Katrin, et al.
Publicado: (2021)

Artificial Intelligence-Based Prognostic Model for Urologic Cancers: A SEER-Based Study
por: Eminaga, Okyaz, et al.
Publicado: (2022)

The Relationship between Prostate Biopsy Results and PSA and Free PSA Ratio Changes in Elevated Serum PSA Patients with and without Antibiotherapy
por: Duran, Mesut Berkan, et al.
Publicado: (2020)

Temperature Control of psaA Expression by PsaE and PsaF in Yersinia pestis
por: Quinn, Joshua D., et al.
Publicado: (2019)

Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide
por: Conteduca, Vincenza, et al.
Publicado: (2022)

Early Prostate-Specific Antigen (PSA) Change at Four Weeks of the First-Line Treatment Using Abiraterone and Enzalutamide Could Predict Early/Primary Resistance in Metastatic Castration-Resistant Prostate Cancer
por: Uchimoto, Taizo, et al.
Publicado: (2021)

Association of Polymorphisms in the Prostate-Specific Antigen (PSA) Gene Promoter with Serum PSA Level and PSA Changes after Dutasteride Treatment in Korean Men with Benign Prostatic Hypertrophy
por: Park, Sung Woon, et al.
Publicado: (2010)

Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection
por: Höti, Naseruddin, et al.
Publicado: (2023)

Prognostic significance of a novel indicator (PSA(postd3)/PSA(pre)) for PSA recurrence in patients after radical prostatectomy
por: Zhou, Zhien, et al.
Publicado: (2019)

Zonal adjusted PSA density improves prostate cancer detection rates compared with PSA in Taiwanese males with PSA < 20 ng/ml
por: Chang, Tsung-Hsin, et al.
Publicado: (2020)

Lenalidomide decreased the PSA level for castration‐resistant prostate cancer: a case report
por: Shimokihara, Kota, et al.
Publicado: (2018)

Improving power in PSA response analyses of metastatic castration-resistant prostate cancer trials
por: Grayling, Michael J., et al.
Publicado: (2022)

Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall Survival
por: Facchini, Gaetano, et al.
Publicado: (2016)

Correlation Between Trough Level of Abiraterone and Prostate-Specific Antigen (PSA) Response in Metastatic Hormone-Sensitive Prostate Cancer
por: Myint, Zin W., et al.
Publicado: (2022)

Establishment of reference intervals for serum [−2]proPSA (p2PSA), %p2PSA and prostate health index in healthy men
por: Wu, Zhi-Yu, et al.
Publicado: (2019)

Exponential Rise in Prostate-Specific Antigen (PSA) during Anti-Androgen Withdrawal Predicts PSA Flare after Docetaxel Chemotherapy in Patients with Castration-Resistant Prostate Cancer
por: Han, Kyung Seok, et al.
Publicado: (2015)

Longitudinal tracking of subpopulation dynamics and molecular changes during LNCaP cell castration and identification of inhibitors that could target the PSA−/lo castration-resistant cells
por: Rycaj, Kiera, et al.
Publicado: (2016)

Detection of prostate cancer with complexed PSA and complexed/total PSA ratio - is there any advantage?
por: Strittmatter, F, et al.
Publicado: (2011)

A Comparative Performance Analysis of Total PSA, Percentage Free PSA, PSA Velocity, and PSA Density versus the Detection of Primary Circulating Prostate Cells in Predicting Initial Prostate Biopsy Findings in Chilean Men
por: Murray, Nigel P., et al.
Publicado: (2014)

Improvement of Prostate Cancer Diagnosis by Detecting PSA Glycosylation-Specific Changes
por: Llop, Esther, et al.
Publicado: (2016)

Identifying men affected by changes in PSA screening in the COVID-19 pandemic
por: Bass, E.J., et al.
Publicado: (2022)

PSA screening – for whom and when?
por: Albers, Peter
Publicado: (2019)

Antigenic determinants of prostate-specific antigen (PSA) and development of assays specific for different forms of PSA.
por: Nilsson, O., et al.
Publicado: (1997)

Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer
por: Tomioka, Atsushi, et al.
Publicado: (2014)

Time to PSA rise differentiates the PSA bounce after HDR and LDR brachytherapy of prostate cancer
por: Burchardt, Wojciech, et al.
Publicado: (2018)

Assessment of the many faces of PsA: single and composite measures in PsA clinical trials
por: McGagh, Dylan, et al.
Publicado: (2020)

PSA 1972 : proceedings of the 1972 biennial meeting philosophy of science association
Publicado: (1974)

Free PSA performs better than total PSA in predicting prostate volume in Chinese men with PSA levels of 2.5–9.9 ng ml(−1)
por: Huang, Ma-Ping, et al.
Publicado: (2022)

Exploration of the Value of Combined UA, IL-6, and fPSA/tPSA in the Diagnosis of Prostate Cancer
por: Tang, Qionghua, et al.
Publicado: (2022)

Improvement of Prostate Cancer Diagnosis by Detecting PSA Glycosylation-Specific Changes: Erratum
por: Llop, Esther, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_o8t8vaj4vrc4jcs6f7637tb93i